Melanoma gene expression profiles to identify mechanisms of tumor resistance

Size: px
Start display at page:

Download "Melanoma gene expression profiles to identify mechanisms of tumor resistance"

Transcription

1 Melanoma gene expression profiles to identify mechanisms of tumor resistance Helena Harlin Human Immunologic Monitoring Facility University of Chicago

2 Introduction High frequencies of melanoma antigen-specific CD8 + T cells induced by vaccination or adoptive transfer do not always translate into tumor regression This observation has prompted investigation into the tumor microenvironment to identify potential factors that positively or negatively regulate the effector phase of an anti-tumor immune response One approach has been to characterize gene expression profiles from metastatic melanoma tumors (core biopsies or resected specimens)

3 Methods RNA was extracted from tumor biopsies of patients with metastatic melanoma (n=33) as well as from melanoma cell lines (n=5) and primary melanocyte cell lines (n=3) Gene array analysis was performed (Affymetrix chip U133A) Data was analyzed using dchip software, filtering for genes present in >1% of samples and with variation of std. dev./mean between 1 and genes with variable gene expression were identified. Genes and samples were clustered using hierarchical cluster analysis. In some cases, gene expression was analyzed using real time RT- PCR, both to confirm gene array data and to look for expression of genes not detected by the chip.

4 The gene array samples cluster into 3 main groups Group 1 Group 3 Group 2

5 Tumor group 1 expresses immunologically relevant transcripts Putative positive factors: Cytokines (IL-18) Chemokine (CCL27) Cytokine receptor (IL-1R) Putative negative factors: Arginase IL-1R antagonist

6 Tumor group 2 expresses T cell, B cell, and other immune cell transcripts Putative positive factors: B cell markers (IgH, Igκ, Igλ) T cell markers (TcRα, β, γ) MΦ markers (MΦ scavenger receptor 1) Complement components Granzyme A, K MHC class II Chemokines (CXCL13, CXCL1, CXCL11, CXCL9, CXCL5, CCL5) Putative negative factors: Indoleamine-pyrrole 2,3 dioxygenase (IDO) Tryptophan 2,3-dioxygenase Angiogenesis factors (angiopoietin 2, angiopoietin 1, VEGF)

7 Tumor group 3 is characterized by a lack of immunologically relevant transcripts and includes melanoma and melanocyte cell lines Expression of various tumor markers: Cancer/testis Ags Melanoma differentiation Ags Oncogenes

8 L 537 el LP el DP l MP L 624 L 888 L 28 L 23 23B L 537 el LP el DP l MP L 624 L 888 L 28 L 23 23B L 537 el LP el DP l MP L 624 L 888 L 28 L 23 23B L 537 el LP el DP l MP L 624 L 888 L 28 L 23 23B T cell, B cell and Mφ transcripts are expressed highly in group 2 tumor samples TcRα TcRβ Igκ constant CD

9 Representative transcripts encoding positive immune factors in tumor groups 1 and 2 IL-18 CD8α

10 IL-1 and IFN-γ transcripts are present variably in tumor samples from both group 1 and group 2 IL-1 IFN-γ 1 2 1e-4 2e-4 3e-4 4e-4 5e-4 6e-4 1e-4 2e-4 3e-4 4e-4 5e-4 6e-4

11 Arginase and IDO expression levels show an inverse correlation Group 1 Group 3 Group CL 537 Mel LP Mel DP Mel MP CL 624 CL 888 CL 28 CL 23 CL 23B 76 5 T T T IDO Arginase

12 Arginase expression validated by real-time RT- PCR is primarily found in group 1 samples Gene array qrt-pcr

13 IDO expression validated by real-time RT-PCR is primarily found in group 2 samples Gene array qrt-pcr

14 Regulatory T cell transcripts in tumor groups 1 and 2 FoxP3 GITR e-5 1.e-4 1.5e-4 2.e-4 2.5e-4 3.e-4 3.5e

15 Additional transcripts encoding putative negative regulators PD-L1 Angiopoietin 1 ND 1 2 1e-4 2e-4 3e-4 4e-4 5e

16 Survivin transcripts are widely expressed, being highest in group 3 tumor cell line samples L 537 el LP el DP l MP L 624 L 888 L 28 L 23 23B

17 Conclusions Metastatic melanoma tumor samples cluster into at least three groups based on gene expression profiling Groups 1 and 2 have distinct gene expression patterns Both contain distinct sets of immunologically relevant genes Include putative negative and positive regulators of T cell function Group 3 lacks immune genes and clusters together with melanoma and primary melanocyte cell lines Suggests defects in inflammatory cell trafficking Group 1 samples express Arginase and group 2 contains all samples with IDO. Arginase and IDO expression are inversely correlated. Therefore, all tumors appear to be accounted for by a putative negative immunoregulatory process: Lack of inflammatory cell migration Expression of inhibitory factors A larger number of samples is currently being analyzed, with planned correlation with clinical outcome Therapeutic strategies to counter inhibitory influences in the tumor microenvironment should be considered for development

18 Acknowledgments University of Chicago Alpana Sahu Todd Kuna Functional Genomics Facility University of Virginia Michael Hanshew Craig Slingluff Amy Peterson Mark McKee Thomas Gajewski

19

20 Angiogenic factors are primarily present among group 2 tumor samples VEGF Angiopoietin

21 CD8α L 537 el LP el DP l MP L 624 L 888 L 28 L 23 23B CD8α CD8β 8 CD8b L 537 el LP el DP l MP L 624 L 888 L 28 L 23 23B CD L 537 el LP el DP l MP L 624 L 888 L 28 L 23 23B CD4 B L 537 el LP el DP l MP L 624 L 888 L 28 L 23 23B B7-1

22 B L 537 el LP el DP l MP L 624 L 888 L 28 L 23 23B B7-2 CTLA L 537 el LP el DP l MP L 624 L 888 L 28 L 23 23B CTLA-4

Regulation of anti-tumor immunity through migration of immune cell subsets within the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D.

Regulation of anti-tumor immunity through migration of immune cell subsets within the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D. Regulation of anti-tumor immunity through migration of immune cell subsets within the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D. Professor, Departments of Pathology and Medicine Program Leader,

More information

Understanding and overcoming immunoregulatory barriers within

Understanding and overcoming immunoregulatory barriers within Understanding and overcoming immunoregulatory barriers within the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D. Professor, Departments of Pathology and Medicine Program Leader, Immunology and

More information

Immunotherapeutic barriers at the level of the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D.

Immunotherapeutic barriers at the level of the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D. Immunotherapeutic barriers at the level of the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D. Professor, Departments of Pathology and Medicine Program Leader, Immunology and Cancer Program of the

More information

Immunotherapeutic barriers at the level of the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D.

Immunotherapeutic barriers at the level of the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D. Immunotherapeutic barriers at the level of the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D. Professor, Departments of Pathology and Medicine Program Leader, Immunology and Cancer Program of the

More information

Molecular mechanisms of the T cellinflamed tumor microenvironment: Implications for cancer immunotherapy

Molecular mechanisms of the T cellinflamed tumor microenvironment: Implications for cancer immunotherapy Molecular mechanisms of the T cellinflamed tumor microenvironment: Implications for cancer immunotherapy Thomas F. Gajewski, M.D., Ph.D. Professor, Departments of Pathology and Medicine Program Leader,

More information

Tumor Microenvironment and Immune Suppression

Tumor Microenvironment and Immune Suppression Tumor Microenvironment and Immune Suppression Hassane M. Zarour,, MD Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh Cancer Institute Hallmarks of Cancer: The Next Generation

More information

Immune Tolerance. Kyeong Cheon Jung. Department of Pathology Seoul National University College of Medicine

Immune Tolerance. Kyeong Cheon Jung. Department of Pathology Seoul National University College of Medicine Immune Tolerance Kyeong Cheon Jung Department of Pathology Seoul National University College of Medicine Immune tolerance Unresponsiveness to an antigen that is induced by previous exposure to that antigen

More information

Allergy and Immunology Review Corner: Chapter 19 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD.

Allergy and Immunology Review Corner: Chapter 19 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD. Allergy and Immunology Review Corner: Chapter 19 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD. Chapter 19: Tolerance, Autoimmunity, and Autoinflammation Prepared

More information

BASIC MECHANISM OF TUMOR IMMUNE SUPPRESSION

BASIC MECHANISM OF TUMOR IMMUNE SUPPRESSION BASIC MECHANISM OF TUMOR IMMUNE SUPPRESSION Zihai Li, M.D., Ph.D. Leader, Cancer Immunology Program Hollings Cancer Center Medical University of South Carolina (MUSC) DISCLOSURE GOALS Understand that immune

More information

Darwinian selection and Newtonian physics wrapped up in systems biology

Darwinian selection and Newtonian physics wrapped up in systems biology Darwinian selection and Newtonian physics wrapped up in systems biology Concept published in 1957* by Macfarland Burnet (1960 Nobel Laureate for the theory of induced immune tolerance, leading to solid

More information

5% of patients with genetic immunodeficiency develop a cancer during their lifetime (200x)

5% of patients with genetic immunodeficiency develop a cancer during their lifetime (200x) Immune surveillance 5% of patients with genetic immunodeficiency develop a cancer during their lifetime (200x) Transplanted patients following an immunosuppressor therapy are 80 times more likely to develop

More information

Supplemental Table I.

Supplemental Table I. Supplemental Table I Male / Mean ± SEM n Mean ± SEM n Body weight, g 29.2±0.4 17 29.7±0.5 17 Total cholesterol, mg/dl 534.0±30.8 17 561.6±26.1 17 HDL-cholesterol, mg/dl 9.6±0.8 17 10.1±0.7 17 Triglycerides,

More information

2/16/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery

2/16/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery C007: Immunology of Melanoma: Mechanisms of Immune Therapies Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los Angeles Biomedical

More information

Targeting tumour associated macrophages in anti-cancer therapies. Annamaria Gal Seminar Series on Drug Discovery Budapest 5 January 2018

Targeting tumour associated macrophages in anti-cancer therapies. Annamaria Gal Seminar Series on Drug Discovery Budapest 5 January 2018 Targeting tumour associated macrophages in anti-cancer therapies Annamaria Gal Seminar Series on Drug Discovery Budapest 5 January 2018 Macrophages: Professional phagocytes of the myeloid lineage APC,

More information

Manipulating the Tumor Environment

Manipulating the Tumor Environment Manipulating the Tumor Environment Vincenzo Bronte Verona University Hospital vincenzo.bronte@univr.it Escape from immune control can be viewed as one of the «Hallmarks of Cancer» D. Hanahan and R. A.

More information

Improving cancer immunotherapy by targeting tumorinduced immune suppression

Improving cancer immunotherapy by targeting tumorinduced immune suppression Improving cancer immunotherapy by targeting tumorinduced immune suppression Author J. Stewart, Trina, J. Smyth, Mark Published 2011 Journal Title Cancer and Metastasis Reviews DOI https://doi.org/10.1007/s10555-011-9280-5

More information

Cancer immunity and immunotherapy. General principles

Cancer immunity and immunotherapy. General principles 1 Cancer immunity and immunotherapy Abul K. Abbas UCSF General principles 2 The immune system recognizes and reacts against cancers The immune response against tumors is often dominated by regulation or

More information

Immune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich

Immune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Immune Checkpoints PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Activation of T cells requires co-stimulation Science 3

More information

Detection of immune cell checkpoint and functional markers in the tumor microenvironment by the RNA in situ hybridization RNAscope assay

Detection of immune cell checkpoint and functional markers in the tumor microenvironment by the RNA in situ hybridization RNAscope assay pplication Note Immunotherapy Detection of immune cell checkpoint and functional markers in the tumor microenvironment by the RN in situ hybridization RNscope assay Ming-Xiao He, Na Li, Courtney nderson,

More information

Immunotherapy for Malignant Brain Cancer: Overcoming Immune Suppression to Improve the Clinical Experience

Immunotherapy for Malignant Brain Cancer: Overcoming Immune Suppression to Improve the Clinical Experience Immunotherapy for Malignant Brain Cancer: Overcoming Immune Suppression to Improve the Clinical Experience Derek Wainwright, PhD Assistant Professor Departments of Neurological Surgery, Microbiology-Immunology

More information

Immune surveillance hypothesis (Macfarlane Burnet, 1950s)

Immune surveillance hypothesis (Macfarlane Burnet, 1950s) TUMOR-IMMUNITÄT A.K. Abbas, A.H. Lichtman, S. Pillai (6th edition, 2007) Cellular and Molecular Immunology Saunders Elsevier Chapter 17, immunity to tumors Immune surveillance hypothesis (Macfarlane Burnet,

More information

The Role of CCR9 and Melanoma Metastasis to Small Intestine. Farin Amersi, MD Samuel Oschin Comprehensive Cancer Center Cedar Sinai Medical Center

The Role of CCR9 and Melanoma Metastasis to Small Intestine. Farin Amersi, MD Samuel Oschin Comprehensive Cancer Center Cedar Sinai Medical Center The Role of CCR9 and Melanoma Metastasis to Small Intestine Farin Amersi, MD Samuel Oschin Comprehensive Cancer Center Cedar Sinai Medical Center BACKGROUND Melanoma is the fifth most common cancer. Estimated

More information

Histological and immunological characteristics of colitis associated with anti-ctla 4 antibody therapy

Histological and immunological characteristics of colitis associated with anti-ctla 4 antibody therapy Histological and immunological characteristics of colitis associated with anti-ctla 4 antibody therapy M. Perdiki 2, G. Bamias 1, D. Pouloudi 2, H. Gogas 3, I. Delladetsima 2 1 Academic Dpt. of Gastroenterology,

More information

The Case of the Spring Break Consequences

The Case of the Spring Break Consequences The Case of the Spring Break Consequences Hazel reluctantly opened her eyes when her alarm went off. Spring Break was over, and she was definitely NOT ready for the second half of the semester. However,

More information

Supplemental materials

Supplemental materials Supplemental materials 1 Supplemental Fig. 1 Immunogram This immunogram summarizes patient clinical data and immune parameters at corresponding time points for Patient IMF-32. The top panel illustrates

More information

Biologic Basis of Immunotherapy in Lung Cancer

Biologic Basis of Immunotherapy in Lung Cancer Biologic Basis of Immunotherapy in Lung Cancer Andrew R. Haas, MD, PhD Director, Interventional Pulmonary and Thoracic Oncology Perelman School of Medicine of the University of Pennsylvania Philadelphia,

More information

The Immune System. Innate. Adaptive. - skin, mucosal barriers - complement - neutrophils, NK cells, mast cells, basophils, eosinophils

The Immune System. Innate. Adaptive. - skin, mucosal barriers - complement - neutrophils, NK cells, mast cells, basophils, eosinophils Objectives - explain the rationale behind cellular adoptive immunotherapy - describe methods of improving cellular adoptive immunotherapy - identify mechanisms of tumor escape from cellular adoptive immunotherapy

More information

5/1/13. The proportion of thymus that produces T cells decreases with age. The cellular organization of the thymus

5/1/13. The proportion of thymus that produces T cells decreases with age. The cellular organization of the thymus T cell precursors migrate from the bone marrow via the blood to the thymus to mature 1 2 The cellular organization of the thymus The proportion of thymus that produces T cells decreases with age 3 4 1

More information

4. Th1-related gene expression in infected versus mock-infected controls from Fig. 2 with gene annotation.

4. Th1-related gene expression in infected versus mock-infected controls from Fig. 2 with gene annotation. List of supplemental information 1. Graph of mouse weight loss during course of infection- Line graphs showing mouse weight data during course of infection days 1 to 10 post-infections (p.i.). 2. Graph

More information

Synergistic effects of indoleamine 2,3-dioxygenase (IDO) inhibitor drugs and chemotherapy in melanoma.

Synergistic effects of indoleamine 2,3-dioxygenase (IDO) inhibitor drugs and chemotherapy in melanoma. Synergistic effects of indoleamine 2,3-dioxygenase (IDO) inhibitor drugs and chemotherapy in melanoma. Madhav D. Sharma Cancer Immunology, Inflammation, and Tolerance Program, Department of Pediatrics,

More information

Tumor Immunity and Immunotherapy. Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School

Tumor Immunity and Immunotherapy. Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School Tumor Immunity and Immunotherapy Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School Lecture Outline Evidence for tumor immunity Types of tumor antigens Generation of anti-tumor

More information

Targeted Therapy in Advanced Renal Cell Carcinoma

Targeted Therapy in Advanced Renal Cell Carcinoma Targeted Therapy in Advanced Renal Cell Carcinoma Brian I. Rini, M.D. Department of Solid Tumor Oncology Glickman Urologic and Kidney Institute Cleveland Clinic Taussig Cancer Institute Cleveland, Ohio

More information

Allergy and Immunology Review Corner: Chapter 13 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD.

Allergy and Immunology Review Corner: Chapter 13 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD. Allergy and Immunology Review Corner: Chapter 13 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD. Chapter 13: Mechanisms of Immunity to Viral Disease Prepared by

More information

TITLE: MODULATION OF T CELL TOLERANCE IN A MURINE MODEL FOR IMMUNOTHERAPY OF PROSTATIC ADENOCARCINOMA

TITLE: MODULATION OF T CELL TOLERANCE IN A MURINE MODEL FOR IMMUNOTHERAPY OF PROSTATIC ADENOCARCINOMA AD Award Number: DAMD17-01-1-0085 TITLE: MODULATION OF T CELL TOLERANCE IN A MURINE MODEL FOR IMMUNOTHERAPY OF PROSTATIC ADENOCARCINOMA PRINCIPAL INVESTIGATOR: ARTHUR A HURWITZ, Ph.d. CONTRACTING ORGANIZATION:

More information

The quest for the identification of the genetic determinants of cancer immune responsiveness

The quest for the identification of the genetic determinants of cancer immune responsiveness 2015 Sidra Medical and Research Center The quest for the identification of the genetic determinants of cancer immune responsiveness Francesco M Marincola - Chief Research Officer Sidra Medical and Research

More information

CELLULAR AND MOLECULAR REQUIREMENTS FOR REJECTION OF B16 MELANOMA IN THE SETTING OF REGULATORY T CELL DEPLETION AND HOMEOSTATIC PROLIFERATION

CELLULAR AND MOLECULAR REQUIREMENTS FOR REJECTION OF B16 MELANOMA IN THE SETTING OF REGULATORY T CELL DEPLETION AND HOMEOSTATIC PROLIFERATION CELLULAR AND MOLECULAR REQUIREMENTS FOR REJECTION OF B16 MELANOMA IN THE SETTING OF REGULATORY T CELL DEPLETION AND HOMEOSTATIC PROLIFERATION Justin Kline 1, Long Zhang 1, and Thomas F. Gajewski 1,2 Departments

More information

The development of T cells in the thymus

The development of T cells in the thymus T cells rearrange their receptors in the thymus whereas B cells do so in the bone marrow. The development of T cells in the thymus The lobular/cellular organization of the thymus Immature cells are called

More information

Cytokines: Interferons, Interleukins and Beyond. Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center

Cytokines: Interferons, Interleukins and Beyond. Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center Cytokines: Interferons, Interleukins and Beyond Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center Disclosures Advisory Boards: Bristol-Myers Squibb,Amgen, Novartis, Alkermes, Infinity,

More information

Scott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION

Scott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION Scott Abrams, Ph.D. Professor of Oncology, x4375 scott.abrams@roswellpark.org Kuby Immunology SEVENTH EDITION CHAPTER 11 T-Cell Activation, Differentiation, and Memory Copyright 2013 by W. H. Freeman and

More information

VISTA, a novel immune checkpoint protein ligand that suppresses anti-tumor tumor T cell responses. Li Wang. Dartmouth Medical School

VISTA, a novel immune checkpoint protein ligand that suppresses anti-tumor tumor T cell responses. Li Wang. Dartmouth Medical School VISTA, a novel immune checkpoint protein ligand that suppresses anti-tumor tumor T cell responses Li Wang Dartmouth Medical School The B7 Immunoglobulin Super-Family immune regulators APC T cell Co-stimulatory:

More information

Cytokine Arrays Reveal Black Ops Tactics of Tumor-induced Immunosuppression

Cytokine Arrays Reveal Black Ops Tactics of Tumor-induced Immunosuppression Cytokine Arrays Reveal Black Ops Tactics of Tumor-induced Immunosuppression Jarad J Wilson, Ph.D. Technical Support & Marketing Specialist Ruo-Pan Huang, MD, Ph.D. Founder and CEO What are Antibody Arrays?

More information

Transcript-indexed ATAC-seq for immune profiling

Transcript-indexed ATAC-seq for immune profiling Transcript-indexed ATAC-seq for immune profiling Technical Journal Club 22 nd of May 2018 Christina Müller Nature Methods, Vol.10 No.12, 2013 Nature Biotechnology, Vol.32 No.7, 2014 Nature Medicine, Vol.24,

More information

Tumors arise from accumulated genetic mutations. Tumor Immunology (Cancer)

Tumors arise from accumulated genetic mutations. Tumor Immunology (Cancer) Tumor Immunology (Cancer) Tumors arise from accumulated genetic mutations Robert Beatty MCB150 Mutations Usually have >6 mutations in both activation/growth factors and tumor suppressor genes. Types of

More information

ONCOSEC ARMING THE IMMUNE SYSTEM TO FIGHT CANCER NASDAQ: ONCS

ONCOSEC ARMING THE IMMUNE SYSTEM TO FIGHT CANCER NASDAQ: ONCS ONCOSEC TM ARMING THE IMMUNE SYSTEM TO FIGHT CANCER NASDAQ: ONCS 0 Forward Looking Statements Our commentary and responses to your questions may contain forward looking statements, as described in the

More information

Division of Immunology 1 Blackfan Circle Boston, MA (617) Title: Orthopox Immunization in patients with cancer or eczema

Division of Immunology 1 Blackfan Circle Boston, MA (617) Title: Orthopox Immunization in patients with cancer or eczema Title: Orthopox Immunization in patients with cancer or eczema Principal Investigator: Ellis Rheinherz, MD Researchers Involved: Robert Fuhlbrigge MD, PhD Summary: The major goals of this Cooperative Center

More information

Venky Ramakrishna PhD Celldex Therapeutics, Hampton NJ, USA

Venky Ramakrishna PhD Celldex Therapeutics, Hampton NJ, USA Antibody Targeting of Human CD27 with Varlilumab (CDX-1127) identifies genes and pathways related to inflammation Venky Ramakrishna PhD Celldex Therapeutics, Hampton NJ, USA www.celldextherapeutics.com

More information

Chapter 2 The Role of the Immune System and Immunoregulatory Mechanisms Relevant to Melanoma

Chapter 2 The Role of the Immune System and Immunoregulatory Mechanisms Relevant to Melanoma Chapter 2 The Role of the Immune System and Immunoregulatory Mechanisms Relevant to Melanoma Cara Haymaker, Geok Choo Sim, Marie-Andree Forget, Jie Qing Chen, Chantale Bernatchez, and Laszlo Radvanyi Abstract

More information

Supplementary Table 1 Clinicopathological characteristics of 35 patients with CRCs

Supplementary Table 1 Clinicopathological characteristics of 35 patients with CRCs Supplementary Table Clinicopathological characteristics of 35 patients with CRCs Characteristics Type-A CRC Type-B CRC P value Sex Male / Female 9 / / 8.5 Age (years) Median (range) 6. (9 86) 6.5 (9 76).95

More information

Innate and adaptive immune cells in the tumor microenvironment

Innate and adaptive immune cells in the tumor microenvironment TISSUE-RESIDENT LEUKOCYTES Innate and adaptive immune cells in the tumor microenvironment Thomas F Gajewski, Hans Schreiber & Yang-Xin Fu Most tumor cells express antigens that can mediate recognition

More information

Immunological parameters as a new lead in the diagnosis of ovarian cancer

Immunological parameters as a new lead in the diagnosis of ovarian cancer Facts Views Vis Obgyn, 2015, 7 (1): 67-72 Viewpoint Immunological parameters as a new lead in the diagnosis of ovarian cancer T. Baert 1,2, D. Timmerman,1,3, I. Vergote 1,2, A. Coosemans 1,2 1 UZ Leuven,

More information

Rationale for Combining Immunotherapy with Chemotherapy or Targeted Therapy

Rationale for Combining Immunotherapy with Chemotherapy or Targeted Therapy Society for Immunotherapy of Cancer (SITC) Rationale for Combining Immunotherapy with Chemotherapy or Targeted Therapy Qing Yi, MD, PhD Staff and Chair, Department of Cancer Biology Betsy B. DeWindt Endowed

More information

HARNESS THE POWER OF THE IMMUNE SYSTEM TO FIGHT CANCER

HARNESS THE POWER OF THE IMMUNE SYSTEM TO FIGHT CANCER OncoPept TM HARNESS THE POWER OF THE IMMUNE SYSTEM TO FIGHT CANCER OncoPept identifies and delivers priortized T-cell neo-epitopes from the patient's tumor mutanome 2 What is OncoPept? OncoPept is an integrated

More information

Initiation and regulation of effector T cell responses in the prostate

Initiation and regulation of effector T cell responses in the prostate University of Iowa Iowa Research Online Theses and Dissertations 2011 Initiation and regulation of effector T cell responses in the prostate Jessica M. Haverkamp University of Iowa Copyright 2011 Jessica

More information

Basic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression. Bryon Johnson, PhD

Basic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression. Bryon Johnson, PhD Basic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression Bryon Johnson, PhD Disclosures There will be discussion about the use of products for non-fda indications in this presentation.

More information

Immunotherapy of cancer: present status and future promise : Danish Cancer Society Symposium, Copenhagen, Denmark, 23rd 25th September 2013

Immunotherapy of cancer: present status and future promise : Danish Cancer Society Symposium, Copenhagen, Denmark, 23rd 25th September 2013 DOI 10.1007/s00262-014-1585-0 Meeting Report Immunotherapy of cancer: present status and future promise : Danish Cancer Society Symposium, Copenhagen, Denmark, 23rd 25th September 2013 Marco Donia Rikke

More information

Blocking antibodies and peptides. Rat anti-mouse PD-1 (29F.1A12, rat IgG2a, k), PD-

Blocking antibodies and peptides. Rat anti-mouse PD-1 (29F.1A12, rat IgG2a, k), PD- Supplementary Methods Blocking antibodies and peptides. Rat anti-mouse PD-1 (29F.1A12, rat IgG2a, k), PD- L1 (10F.9G2, rat IgG2b, k), and PD-L2 (3.2, mouse IgG1) have been described (24). Anti-CTLA-4 (clone

More information

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President

More information

General Overview of Immunology. Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center

General Overview of Immunology. Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center General Overview of Immunology Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center Objectives Describe differences between innate and adaptive immune responses

More information

International Society of Breast Pathology. Immune Targeting in Breast Cancer. USCAP 2017 Annual Meeting

International Society of Breast Pathology. Immune Targeting in Breast Cancer. USCAP 2017 Annual Meeting International Society of Breast Pathology USCAP 2017 Annual Meeting Immune Targeting in Breast Cancer Ashley Cimino-Mathews, MD Assistant Professor of Pathology and Oncology The Johns Hopkins Hospital

More information

NewLink Genetics Corporation

NewLink Genetics Corporation Stifel Healthcare Conference Presentation NewLink Genetics Corporation NASDAQ: NLNK November 13, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements

More information

Major Histocompatibility Complex (MHC) and T Cell Receptors

Major Histocompatibility Complex (MHC) and T Cell Receptors Major Histocompatibility Complex (MHC) and T Cell Receptors Historical Background Genes in the MHC were first identified as being important genes in rejection of transplanted tissues Genes within the MHC

More information

Tumor Immunology: A Primer

Tumor Immunology: A Primer Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including

More information

Immunotherapy, an exciting era!!

Immunotherapy, an exciting era!! Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy

More information

T Cell Activation, Costimulation and Regulation

T Cell Activation, Costimulation and Regulation 1 T Cell Activation, Costimulation and Regulation Abul K. Abbas, MD University of California San Francisco 2 Lecture outline T cell antigen recognition and activation Costimulation, the B7:CD28 family

More information

Interleukin-2 Single Agent and Combinations

Interleukin-2 Single Agent and Combinations Interleukin-2 Single Agent and Combinations Michael K Wong MD PhD Norris Cancer Center University of Southern California mike.wong@med.usc.edu Disclosures Advisory Board Attendance Merck Bristol Myers

More information

Regulating the Regulators for Cancer Immunotherapy: LAG-3 Finally Catches Up. Drew Pardoll Sidney Kimmel Cancer Center Johns Hopkins

Regulating the Regulators for Cancer Immunotherapy: LAG-3 Finally Catches Up. Drew Pardoll Sidney Kimmel Cancer Center Johns Hopkins Regulating the Regulators for Cancer Immunotherapy: LAG-3 Finally Catches Up Drew Pardoll Sidney Kimmel Cancer Center Johns Hopkins The hostile immune microenvironment within a tumor Stat3 Stat3 NK Lytic

More information

Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation

Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation C. Andrew Stewart,, Werner Müller, Giorgio Trinchieri J Clin Invest. 2013;123(11):4859-4874. https://doi.org/10.1172/jci65180.

More information

Emerging Concepts of Cancer Immunotherapy

Emerging Concepts of Cancer Immunotherapy Emerging Concepts of Cancer Immunotherapy Jeffrey Schlom, Ph.D. Laboratory of Tumor Immunology and Biology (LTIB) Center for Cancer Research National Cancer Institute, NIH Immune Cell Infiltrate in Primary

More information

State of the Art 3: Immunotherapy and Modulators of Apoptosis

State of the Art 3: Immunotherapy and Modulators of Apoptosis State of the Art 3: Immunotherapy and Modulators of Apoptosis James Finke, PhD - Cleveland Clinic, Immunology Crystal Mackall, MD - NCI, Pediatric Oncology James Mier, MD - BIDMC, Medical Oncology Craig

More information

Supplementary Figure 1. IDH1 and IDH2 mutation site sequences on WHO grade III

Supplementary Figure 1. IDH1 and IDH2 mutation site sequences on WHO grade III Supplementary Materials: Supplementary Figure 1. IDH1 and IDH2 mutation site sequences on WHO grade III patient samples. Genomic DNA samples extracted from punch biopsies from either FFPE or frozen tumor

More information

Glioma cancer stem cells mediate immune suppression that can be reversed with STAT3 blockade

Glioma cancer stem cells mediate immune suppression that can be reversed with STAT3 blockade Glioma cancer stem cells mediate immune suppression that can be reversed with STAT3 blockade Jun Wei Department of Neurosurgery October 23, 2009 Immune suppression in Malignant Glioma Patients Mechanisms

More information

Lessons learned from the blockade of immune checkpoints in cancer immunotherapy

Lessons learned from the blockade of immune checkpoints in cancer immunotherapy Li et al. Journal of Hematology & Oncology (2018) 11:31 https://doi.org/10.1186/s13045-018-0578-4 REVIEW Lessons learned from the blockade of immune checkpoints in cancer immunotherapy Xiaolei Li 1,2,

More information

Effector T Cells and

Effector T Cells and 1 Effector T Cells and Cytokines Andrew Lichtman, MD PhD Brigham and Women's Hospital Harvard Medical School 2 Lecture outline Cytokines Subsets of CD4+ T cells: definitions, functions, development New

More information

Cancer and the Immune System

Cancer and the Immune System NIFA Neue Impulse in Fortbildung und Ausbildung, AstraZeneca Onkologie Symposium, Vienna, October 20 th 2017 Cancer and the Immune System Translational Tumor Immunology Group, Ludwig Cancer Research Center

More information

Adenovirus engineered human dendritic cell vaccine induces natural killer cell chemotaxis

Adenovirus engineered human dendritic cell vaccine induces natural killer cell chemotaxis Adenovirus engineered human dendritic cell vaccine induces natural killer cell chemotaxis via CXCL8/IL 8 and CXCL10/IP 10 chemokines Lazar Vujanović, Ph.D. Research Instructor P.I. Lisa H. Butterfield,

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION Table S1: Combination Immunotherapy: Small Molecules that Boost Immune Response in Combination with Other Agents Target Compound (MOA) NLG919 and indoximod 1- MT Combination Model Observation Reference

More information

Regulatory T cells in multiple sclerosis and myasthenia gravis

Regulatory T cells in multiple sclerosis and myasthenia gravis Danikowski et al. Journal of Neuroinflammation (2017) 14:117 DOI 10.1186/s12974-017-0892-8 REVIEW Regulatory T cells in multiple sclerosis and myasthenia gravis K. M. Danikowski, S. Jayaraman and B. S.

More information

Coxsackievirus A21: The basic facts

Coxsackievirus A21: The basic facts Phase II CALM Extension study: Intratumoral CAVATAK TM increases immune- cell infiltrates and up- regulates immune- checkpoint molecules in the microenvironment of lesions from advanced melanoma padents

More information

Corso di Laurea Specialistica in Biotecnologie Molecolari aa 2006/2007 Presentazione di Immunologia Molecolare INTERFERON GAMMA.

Corso di Laurea Specialistica in Biotecnologie Molecolari aa 2006/2007 Presentazione di Immunologia Molecolare INTERFERON GAMMA. Corso di Laurea Specialistica in Biotecnologie Molecolari aa 2006/2007 Presentazione di Immunologia Molecolare INTERFERON GAMMA Valentina Grosso The Inteferons 1957: Isaacs and Lindenmann discovered a

More information

Stergios Moschos, MD

Stergios Moschos, MD Stergios Moschos, MD Clinical Associate Professor of Medicine Department of Medicine Division of Hematology/Oncology University of North Carolina at Chapel Hill Solid Tumor with one of the Highest Mutation

More information

Supplemental Information. IRF-5 Promotes Cell Death in CD4 T Cells. during Chronic Infection

Supplemental Information. IRF-5 Promotes Cell Death in CD4 T Cells. during Chronic Infection Cell Reports, Volume 24 Supplemental Information IRF-5 Promotes Cell Death in T Cells during Chronic Infection Aymeric Fabié, Linh Thuy Mai, Xavier Dagenais-Lussier, Akil Hammami, Julien van Grevenynghe,

More information

Tumor Immune Escape Mechanisms

Tumor Immune Escape Mechanisms Chapter 31 / Tumor Immune Escape Mechanisms 577 31 Tumor Immune Escape Mechanisms Yi Ting Koh, BSc, M. Luz García-Hernández, PhD, and W. Martin Kast, PhD CONTENTS INTRODUCTION: IMMUNOSURVEILLANCE OF CANCER

More information

NewLink Genetics Corporation

NewLink Genetics Corporation Cantor Fitzgerald 2018 Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK October 3, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking

More information

Chapter 7 Conclusions

Chapter 7 Conclusions VII-1 Chapter 7 Conclusions VII-2 The development of cell-based therapies ranging from well-established practices such as bone marrow transplant to next-generation strategies such as adoptive T-cell therapy

More information

IMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust

IMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent

More information

Disclosure Information. Mary L. Disis

Disclosure Information. Mary L. Disis Disclosure Information Mary L. Disis I have the following financial relationships to disclose: Consultant for: VentiRx, Celgene, Emergent, EMD Serono Speaker s Bureau for: N/A Grant/Research support from:

More information

Jason J. Luke 1, Yuanyuan Zha 1, Karen Matijevich 1 and Thomas F. Gajewski 1,2*

Jason J. Luke 1, Yuanyuan Zha 1, Karen Matijevich 1 and Thomas F. Gajewski 1,2* Luke et al. Journal for ImmunoTherapy of Cancer (2016) 4:35 DOI 10.1186/s40425-016-0140-2 RESEARCH ARTICLE Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively

More information

Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017

Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The goal of this MONTHLY

More information

Novel strategies for enhancing the efficacy of therapeutic immunization against cancer Draghiciu, Oana

Novel strategies for enhancing the efficacy of therapeutic immunization against cancer Draghiciu, Oana University of Groningen Novel strategies for enhancing the efficacy of therapeutic immunization against cancer Draghiciu, Oana IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's

More information

Emerging Tissue and Serum Markers

Emerging Tissue and Serum Markers Emerging Tissue and Serum Markers for Immune Checkpoint Inhibitors Kyong Hwa Park MD, PhD Medical Oncology Korea University College of Medicine Contents Immune checkpoint inhibitors in clinical practice

More information

Developing Novel Immunotherapeutic Cancer Treatments for Clinical Use

Developing Novel Immunotherapeutic Cancer Treatments for Clinical Use Developing Novel Immunotherapeutic Cancer Treatments for Clinical Use Oncology for Scientists March 8 th, 2016 Jason Muhitch, PhD Assistant Professor Department of Urology Email: jason.muhitch@roswellpark.org

More information

Advances in Cancer Immunotherapy

Advances in Cancer Immunotherapy Advances in Cancer Immunotherapy Immunology 101 for the Non-Immunologist Arnold H. Zea, PhD azea@lsuhsc.edu Disclosures No relevant financial relationships to disclose This presentation does not contain

More information

Oligometastases: Radiotherapy

Oligometastases: Radiotherapy Oligometastases: Radiotherapy Prof. Dirk De Ruysscher, MD, PhD Radiation Oncologist Maastro clinic, Maastricht University Medical Center/ GROW Maastricht The Netherlands Disclosure Advisory board of Bristol-Myers

More information

The head and neck cancer immune landscape and its immunotherapeutic implications

The head and neck cancer immune landscape and its immunotherapeutic implications The head and neck cancer immune landscape and its immunotherapeutic implications Rajarsi Mandal,, Timothy A. Chan, Luc G.T. Morris JCI Insight. 2016;1(17):e89829. https://doi.org/10.1172/jci.insight.89829.

More information

Immunological biomarkers predictive of clinical response to chemotherapy and maintenance HAART in HIV + patients with Kaposi sarcoma

Immunological biomarkers predictive of clinical response to chemotherapy and maintenance HAART in HIV + patients with Kaposi sarcoma P909 Immunological biomarkers predictive of clinical response to chemotherapy and maintenance HAART in HIV + patients with Kaposi sarcoma Tedeschi R, Bidoli E 2, Bortolin MT, Pratesi C, Basaglia G, Zanussi

More information

Immune response to infection

Immune response to infection Immune response to infection Dr. Sandra Nitsche (Sandra.Nitsche@rub.de ) 20.06.2018 1 Course of acute infection Typical acute infection that is cleared by an adaptive immune reaction 1. invasion of pathogen

More information

Mesenchymal Stem Cells

Mesenchymal Stem Cells Mesenchymal Stem Cells Science and therapeutic applications Dirk Büscher (Former VP-R&D Cellerix) GRIFOLS SA May 10 th, 2010 EMA 1 Discovery and Definition of Mesenchymal Stem Cells MSC must be plastic-adherent

More information

Adoptive Cell Therapy: Treating Cancer

Adoptive Cell Therapy: Treating Cancer Adoptive Cell Therapy: Treating Cancer with Genetically Engineered T Cells Steven A. Feldman, Ph.D. Surgery Branch National Cancer Institute NCT Conference Heidelberg, Germany September 24, 2013 Three

More information

Cancer Immunotherapy: Active Immunization Approaches

Cancer Immunotherapy: Active Immunization Approaches Cancer Immunotherapy: Active Immunization Approaches Willem W. Overwijk, PhD Department of Melanoma Medical Oncology MD Anderson Cancer Center Houston, TX, USA Disclosures No relevant financial relationships

More information

Letter to Editor Tissue micro arrays for immunohistochemical detection of inflammatory infiltrates in renal cell carcinoma

Letter to Editor Tissue micro arrays for immunohistochemical detection of inflammatory infiltrates in renal cell carcinoma Int J Clin Exp Med 2014;7(4):1175-1179 www.ijcem.com /ISSN:1940-5901/IJCEM0000102 Letter to Editor Tissue micro arrays for immunohistochemical detection of inflammatory infiltrates in renal cell carcinoma

More information